Parathyroid carcinoma is an endocrine
malignancy with poor outcomes. Its
incidence is low and the molecular mechanisms related with
carcinogenesis and development remains largely unknown. It is difficult to
diagnose and manage
parathyroid carcinoma. In this
review, the recent advances in the molecular mechanism of
parathyroid carcinoma are summarized, with emphasis on the prospects for
future clinical applications.